ArticleCancer gene therapy2026
The role of hsa_circ_0000520 in breast cancer progression: insights into the miR-542-3p/TMBIM6 regulatory axis.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrated bulk, single-cell and spatial transcriptomic analyses identify KIFC1 as a driver of malignant progression in lung adenocarcinoma.Molecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work evaluated the action of hsa_circ_0000520 in breast cancer (BC) progression through miR-542-3p/TMBIM6 axis. Clinical specimens were harvested from BC patients, in which hsa_circ_0000520 expression was determined. BT-549 cells were taken for transfection to intervene gene expression correspondingly, after which cellular proliferative, invasive, migratory, and apoptotic activities were monitored. As well, under different treatment, the changes in relevant indicators were observed. A tumor model was established in mice to examine the action of hsa_circ_0000520. Mechanistic analysis using RIP and lufiferase reporter assay were conducted to verify the interaction between miR-542-3p and hsa_circ_0000520 or TMBIM6. hsa_circ_0000520 was elevated in its expression in BC tissues. hsa_circ_0000520 knockdown exerted an anti-tumor property to fight against cellular malignant phenotypes in vitro, as well as tumor development in vivo. hsa_circ_0000520, through an absorption effect, regulated miR-542-3p, thereby targeting TMBIM6. miR-542-3p upregulation or TMBIM6 downregulation counter-balanced the pro-tumor effects of hsa_circ_0000520 overexpression. hsa_circ_0000520 promotes BC proliferation and metastasis through miR-542-3p-targeted TMBIM6.
Indexed as
Identifiers
41413714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.